DURHAM, N.C.--(BUSINESS WIRE)--HyperBranch Medical Technology, Inc. announced the start of the pivotal portion of the clinical study for Adherus Dural Sealant. This is a key step in the process to gain FDA approval for the product. Enrollment at eight US hospitals began in September 2010 with up to 30 US sites participating in the pivotal trial. The Company successfully completed a U.S. feasibility study for the Adherus Dural Sealant in May, 2010.
